Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 22
HOS-086324 · Präparat HOS-083284
Buspirone Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits
CYP3A and as a result is expected to increase the plasma concentrations of
buspirone. Careful monitoring of therapeutic and adverse effects is recommended
when buspirone concomitantly administered with ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): buspirone (HOS-086325)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage fa341ccc1722e699462ec114c334073cb82e0dc1ca8dea133dbb36d83bea9c95 · Zeichen 54028–54473 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 55
HOS-086487 · Präparat HOS-083284
Buspirone Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits
CYP3A and as a result is expected to increase the plasma concentrations of buspirone.
Careful monitoring of therapeutic and adverse effects is recommended when buspirone
concomitantly administered with ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): buspirone (HOS-086325)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage af67e2a68c1e36d5b2b97ce04c971e64d1196ce08a6f94617ee39e8463ff033e · Zeichen 56374–56823 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 23–24
HOS-116425 · Präparat HOS-094447
23
For the treatment of Not studied. Concomitant use of A safe and effective dose of
pulmonary arterial sildenafil or tadalafil for the treatment of sildenafil for the treatment of
hypertension pulmonary arterial hypertension and pulmonary arterial hypertension
Sildenafil boosted PREZISTA may increase plasma co-administered with boosted
Tadalafil concentrations of sildenafil or tadalafil. PREZISTA has not been
(CYP3A inhibition) established. There is an increased
potential for sildenafil-associated
adverse events (including visual
disturbances, hypotension,
prolonged erection and syncope).
Therefore, co-administration of
boosted PREZISTA and sildenafil
when used for the treatment of
pulmonary arterial hypertension is
contraindicated (see section 4.3).
Co-administration of tadalafil for
the treatment of pulmonary arterial
hypertension with boosted
PREZISTA is not recommended.
PROTON PUMP INHIBITORS
Omeprazole # Boosted PREZISTA can be
darunavir AUC ↔
20 mg once daily #
darunavir Cmin ↔ co-administered with proton pump
#
darunavir Cmax ↔ inhibitors without dose
adjustments.
SEDATIVES/HYPNOTICS
Buspirone Not studied. Sedative/hypnotics are Clinical monitoring is
Clorazepate extensively metabolised by CYP3A. recommended when
Diazepam Co-administration with boosted co-administering boosted
Estazolam PREZISTA may cause a large increase in PREZISTA with these
Flurazepam the concentration of these medicines. sedatives/hypnotics and a lower
Midazolam (parenteral) dose of the sedatives/hypnotics
Zolpidem should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tadalafil (HOS-086316) estazolam (HOS-086165) clorazepate (HOS-086164) diazepam (HOS-085904) zolpidem (HOS-086327) buspirone (HOS-086325) sildenafil (HOS-086162) flurazepam (HOS-086166) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 9634d5188deeb063704d3dec6fa9fde3f4c10970d03131c50c223d1e001e36d7 · Zeichen 72803–75985 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 65–66
HOS-116532 · Präparat HOS-094447
65
For the treatment of Not studied. Concomitant use of A safe and effective dose of
pulmonary arterial sildenafil or tadalafil for the treatment of sildenafil for the treatment of
hypertension pulmonary arterial hypertension and pulmonary arterial hypertension
Sildenafil darunavir co-administered with low dose co-administered with PREZISTA
Tadalafil ritonavir may increase plasma and low dose ritonavir has not
concentrations of sildenafil or tadalafil. been established. There is an
(CYP3A inhibition) increased potential for
sildenafil-associated adverse
events (including visual
disturbances, hypotension,
prolonged erection and syncope).
Therefore, co-administration of
PREZISTA with low dose
ritonavir and sildenafil when used
for the treatment of pulmonary
arterial hypertension is
contraindicated (see section 4.3).
Co-administration of tadalafil for
the treatment of pulmonary arterial
hypertension with PREZISTA and
low dose ritonavir is not
recommended.
PROTON PUMP INHIBITORS
Omeprazole # PREZISTA co-administered with
darunavir AUC ↔
20 mg once daily #
darunavir Cmin ↔ low dose ritonavir can be
#
darunavir Cmax ↔ co-administered with proton pump
inhibitors without dose
adjustments.
SEDATIVES/HYPNOTICS
Buspirone Not studied. Sedative/hypnotics are Clinical monitoring is
Clorazepate extensively metabolised by CYP3A. recommended when
Diazepam Co-administration with co-administering PREZISTA with
Estazolam PREZISTA/ritonavir may cause a large these sedatives/hypnotics and a
Flurazepam increase in the concentration of these lower dose of the
Midazolam (parenteral) medicines. sedatives/hypnotics should be
Zolpidem considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tadalafil (HOS-086316) estazolam (HOS-086165) clorazepate (HOS-086164) diazepam (HOS-085904) zolpidem (HOS-086327) buspirone (HOS-086325) sildenafil (HOS-086162) ritonavir (HOS-084521) flurazepam (HOS-086166) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage d55e033062b465321f1e7d6496fca1203bde2ceee842c6b87a58cc57f689d470 · Zeichen 63956–67534 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 105–106
HOS-116621 · Präparat HOS-094447
105
PROTON PUMP INHIBITORS
Omeprazole # Boosted PREZISTA can be
darunavir AUC ↔
20 mg once daily #
darunavir Cmin ↔ co-administered with proton pump
#
darunavir Cmax ↔ inhibitors without dose
adjustments.
SEDATIVES/HYPNOTICS
Buspirone Not studied. Sedative/hypnotics are Clinical monitoring is
Clorazepate extensively metabolised by CYP3A. recommended when
Diazepam Co-administration with boosted co-administering boosted
Estazolam PREZISTA may cause a large increase in PREZISTA with these
Flurazepam the concentration of these medicines. sedatives/hypnotics and a lower
Midazolam (parenteral) dose of the sedatives/hypnotics
Zolpidem should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): estazolam (HOS-086165) clorazepate (HOS-086164) diazepam (HOS-085904) zolpidem (HOS-086327) buspirone (HOS-086325) flurazepam (HOS-086166) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage a73d9af50672fdd14c65bde9d86094db034ee45f6e6d86b95e800c8a40b7c035 · Zeichen 74475–75820 im Abschnitt
Wechselwirkungen · Methylthioninium chloride Proveblue
Methylthioninium chloride Proveblue 5 mg/ml solution for injection · Abschnitt 4.5 · PDF-Seite 5
HOS-213653 · Präparat HOS-155158
Methylthioninium chloride should be avoided in patients receiving medicinal products that enhance
serotonergic transmission because of the potential for serious CNS reactions, including potentially fatal
serotonin syndrome. These include SSRIs (selective serotonin reuptake inhibitors), bupropion,
buspirone, clomipramine, mirtazapine, and venlafaxine. Opioids, for example, tramadol, fentanyl,
pethidine, and dextromethorphan, may also increase the risk of developing serotonin syndrome, when
used in combination with methylthioninium chloride. If the intravenous use of methylthioninium
chloride cannot be avoided in patients treated with serotonergic medicinal products, the lowest possible
dose should be chosen and the patient observed closely for central nervous system (CNS) effects for up
to 4 hours after administration (see sections 4.4 and 4.8).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) venlafaxine (HOS-086573) serotonin (HOS-085477) clomipramine (HOS-085906) mirtazapine (HOS-144406) buspirone (HOS-086325) fentanyl (HOS-086196) dextromethorphan (HOS-109265) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-19T17:19:00Z · SHA-256 19c53bf82f55a8d25e4c6a9ce5fce20575d1af796cef659dc721231268971317 · Passage 5d108e81ebe37e06fa7a97ec420e29ae2832486a9d97d04b89c9ed6e3c9daf74 · Zeichen 0–856 im Abschnitt
Wechselwirkungen · Sivextro
Sivextro 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-130235 · Präparat HOS-096879
Serotonergic interactions
The potential for serotonergic interactions has not been studied in either patients or healthy volunteers
(see sections 4.4 and 5.2). In Phase 3 studies, subjects taking serotonergic agents including
antidepressants such as selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, and
serotonin 5-hydroxytryptamine (5-HT1) receptor agonists (triptans), meperidine, or buspirone were
excluded.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): serotonin (HOS-085477) buspirone (HOS-086325) meperidine (HOS-114839)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-08T12:22:00Z · SHA-256 67755293d17b65838d18c0065efbf6826bb5cdd2698a851f617dd402e701dbd8 · Passage c5c71a9c63b64202ec2d2a9511db971cde40e1a8689b51e89de9169409117259 · Zeichen 868–1305 im Abschnitt
Wechselwirkungen · Sivextro
Sivextro 200 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 18
HOS-130263 · Präparat HOS-096879
Serotonergic interactions
The potential for serotonergic interactions has not been studied in either patients or healthy volunteers
(see sections 4.4 and 5.2). In Phase 3 studies, subjects taking serotonergic agents including
antidepressants such as selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, and
serotonin 5-hydroxytryptamine (5-HT1) receptor agonists (triptans), meperidine, or buspirone were
excluded.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): serotonin (HOS-085477) buspirone (HOS-086325) meperidine (HOS-114839)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-08T12:22:00Z · SHA-256 67755293d17b65838d18c0065efbf6826bb5cdd2698a851f617dd402e701dbd8 · Passage c5c71a9c63b64202ec2d2a9511db971cde40e1a8689b51e89de9169409117259 · Zeichen 868–1305 im Abschnitt
Wechselwirkungen · Sivextro
Sivextro 245 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 35
HOS-130288 · Präparat HOS-096879
Serotonergic interactions
The potential for serotonergic interactions has not been studied in either patients or healthy volunteers
(see sections 4.4 and 5.2). In Phase 3 studies, subjects taking serotonergic agents including
antidepressants such as selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, and
serotonin 5-hydroxytryptamine (5-HT1) receptor agonists (triptans), meperidine, or buspirone were
excluded.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): serotonin (HOS-085477) buspirone (HOS-086325) meperidine (HOS-114839)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-08T12:22:00Z · SHA-256 67755293d17b65838d18c0065efbf6826bb5cdd2698a851f617dd402e701dbd8 · Passage c5c71a9c63b64202ec2d2a9511db971cde40e1a8689b51e89de9169409117259 · Zeichen 925–1362 im Abschnitt
Wechselwirkungen · Zydelig
Zydelig 100 mg film-coated tablets Zydelig 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-132115 · Präparat HOS-097192
Buspirone, clorazepate, ↑ serum concentrations Concentration monitoring of
diazepam, estazolam, sedatives/hypnotics is recommended
flurazepam, zolpidem and dose reduction may be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): estazolam (HOS-086165) clorazepate (HOS-086164) diazepam (HOS-085904) zolpidem (HOS-086327) buspirone (HOS-086325) flurazepam (HOS-086166)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-21T17:52:00Z · SHA-256 f55f90ba278a87ef1c8e7162344ed4bd66ac7180deaf4c8fda3eca5bbf8e87e5 · Passage 7c4a66355000a66b0c38db8012a4bef0ca7498b9174907a0d2021212a7cee0a4 · Zeichen 13200–13501 im Abschnitt
Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-132861 · Präparat HOS-097310
Monitoring of QT-prolongation if
used concomitantly.
Bortezomib Bortezomib: Careful monitoring.
Busulfan AUC: ↑ 1.4-fold Dose adjustment of each medicinal
Docetaxel Imatinib: product may be required.
Imatinib AUC: ↑ 1.4-fold
Cabazitaxel Cmax: ↑ 1.3-fold
↑in plasma concentrations of
docetaxel have been observed
Potential ↑in plasma concentrations of
busulfan
Cabazitaxel
AUC: ↑ 1.3-fold
Paclitaxel Paclitaxel: Careful monitoring.
No change in plasma concentration were Dose adjustment of paclitaxel
shown with paclitaxel concentrate. No may be required.
studies were performed with albumin
bound nanoparticules.
Vincristine, vinblastine Potential ↑in plasma concentrations of Careful monitoring as it may cause
(vinca alkaloids) vinca alkaloids. an earlier onset and/or an increased
severity of side-effects.
Antipsychotics,
Anxiolytics and
Hypnotics
Triazolam AUC: ↑ have been observed Contraindicated due to the risk of
Alprazolam Cmax: ↑ have been observed potentially prolonged or increased
Midazolam oral sedation and respiratory depression
(see section 4.3).
Lurasidone Lurasidone: Contraindicated due to the increased
AUC: ↑ 9 fold risk of adverse reactions (see section
Cmax: ↑ 6 fold 4.3).
Pimozide Potential ↑in plasma concentrations of Contraindicated due to the risk of
pimozide. serious cardiovascular events
including QT prolongation (see
section 4.3).
Sertindole Potential ↑in plasma concentrations of Contraindicated due to the risk of QT
sertindole. prolongation (see section 4.3).
Quetiapine Quetiapine: Contraindicated as it may increase
AUC: ↑ 6.2-fold quetiapine-related toxicity (see
Cmax: ↑ 3.4-fold section 4.3).
Haloperidol Potential ↑in plasma concentrations of Not recommended due to the
haloperidol. increased risk of QT prolongation
and extrapyramidal symptoms. It
may be necessary to reduce
haloperidol dosage.
Reboxetine Reboxetine: Not recommended because of
AUC: ↑ 1.5-fold of both enantiomers reboxetine narrow’s therapeutic
margin.
Midazolam IV Midazolam: Careful monitoring.
AUC: ↑ 1.6-fold Dose adjustment of midazolam IV
may be required.
11
Medicinal product by Expected effect on drug levels Recommendation for co-
therapeutic area administration
Buspirone Potential ↑in plasma concentrations of Careful monitoring.
buspirone. Dose adjustement of buspirone
may be required.
Aripiprazole Aripiprazole Careful monitoring.
AUC: ↑ 1.6-fold Aripiprazole dose should be reduced
Cmax: ↑ 1.4-fold to approximatively one-half of its
prescribed dose.
Risperidone Potential ↑in AUC of risperidone: Careful monitoring. Dose adjustment
of risperidone may be required.
Antivirals products
Saquinavir Saquinavir: Contraindicated due to the risk of QT
(saquinavir/ritonavir AUC: ↔ prolongation (see section 4.3).
1000/100 mg bid) Cmax: ↔
Ketoconazole
AUC: ↑ 2.7-fold
Cmax:↑ 1.5-fold
(CYP3A4 enzyme inhibition by
ritonavir)
Paritaprevir: Contraindicated due to the increased
AUC: ↑2.2-fold risk of adverse reactions (see section
Cmax: ↑1.7-fold 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): aripiprazole (HOS-129408) sertindole (HOS-085601) quetiapine (HOS-086150) busulfan (HOS-115553) reboxetine (HOS-132863) alprazolam (HOS-086171) vinblastine (HOS-086220) risperidone (HOS-086280) vincristine (HOS-086219) imatinib (HOS-110212) docetaxel (HOS-084505) saquinavir (HOS-084522) bortezomib (HOS-110227) pimozide (HOS-085600) cabazitaxel (HOS-124028) buspirone (HOS-086325) paclitaxel (HOS-087959) haloperidol (HOS-085602) ritonavir (HOS-084521) paritaprevir (HOS-110301) lurasidone (HOS-086148) triazolam (HOS-086168) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage 143b60c2365c220e7ae1ab4873f027ce623544d65995b03a1aab29b618d47f97 · Zeichen 15667–21466 im Abschnitt
Wechselwirkungen · Genvoya
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 19–20
HOS-134030 · Präparat HOS-097520
19
Medicinal product by Effects on medicinal product Recommendation concerning
therapeutic areas levels. co-administration with Genvoya
Mean percent change in AUC,
Cmax, Cmin1
Tricyclic antidepressants (TCAs) Interaction not studied with any of Careful dose titration of the
Trazodone the components of Genvoya. antidepressant and monitoring for
Selective serotonin reuptake antidepressant response is
inhibitors (SSRIs) Concentrations of antidepressant recommended.
Escitalopram agents may be increased when
co-administered with cobicistat.
IMMUNOSUPPRESSANTS
Ciclosporin Interaction not studied with any of Therapeutic monitoring is
Sirolimus the components of Genvoya. recommended upon
Tacrolimus co-administration with Genvoya.
Concentrations of these
immunosuppressant agents may be
increased when administered with
cobicistat.
SEDATIVES/HYPNOTICS
Buspirone Interaction not studied with any of Co-administration of Genvoya and
Clorazepate the components of Genvoya. triazolam is contraindicated (see
Diazepam section 4.3). With other
Estazolam Triazolam is primarily metabolised sedatives/hypnotics, dose reduction
Flurazepam by CYP3A. Co-administration may be necessary and concentration
Lorazepam with Genvoya may result in monitoring is recommended.
Triazolam increased plasma concentrations of
Zolpidem this medicinal product, which is
associated with the potential for
serious or life-threatening adverse
reactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): estazolam (HOS-086165) clorazepate (HOS-086164) lorazepam (HOS-085981) diazepam (HOS-085904) zolpidem (HOS-086327) serotonin (HOS-085477) trazodone (HOS-086251) tacrolimus (HOS-085202) buspirone (HOS-086325) sirolimus (HOS-085172) escitalopram (HOS-129417) triazolam (HOS-086168) flurazepam (HOS-086166)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-28T16:51:00Z · SHA-256 5b1a306ad5f7dd33700254558ee14691810f4eafdcf9d1256ccc229ad5e01997 · Passage 5942209e475c796ef61c4b0bb67f6fad6953705ca4043b5a69de6960506043d8 · Zeichen 46301–48689 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 21–22
HOS-134522 · Präparat HOS-097580
21
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Geometric mean change Recommendations concerning co-
therapeutic areas (%) administration
For the treatment of Not studied. Concomitant use of A safe and effective dose of
pulmonary arterial sildenafil or tadalafil for the treatment sildenafil for the treatment of
hypertension of pulmonary arterial hypertension and pulmonary arterial hypertension co-
Sildenafil darunavir co-administered with low administered with darunavir and
Tadalafil dose ritonavir may increase plasma low dose ritonavir has not been
concentrations of sildenafil or tadalafil. established. There is an increased
(CYP3A inhibition) potential for sildenafil- associated
adverse events (including visual
disturbances, hypotension,
prolonged erection and syncope).
Therefore, co- administration of
darunavir with low dose ritonavir
and sildenafil when used for the
treatment of pulmonary arterial
hypertension is contraindicated (see
section 4.3). Co-administration of
tadalafil for the treatment of
pulmonary arterial hypertension
with darunavir and low dose
ritonavir is not recommended.
PROTON PUMP INHIBITORS
Omeprazole #
darunavir AUC ↔ Darunavir co-administered with low
20 mg once daily #
darunavir Cmin ↔ dose ritonavir can be co-
#
darunavir Cmax ↔ administered with proton pump
inhibitors without dose adjustments.
SEDATIVES/HYPNOTICS
Buspirone Not studied. Sedative/hypnotics are Clinical monitoring is
Clorazepate extensively metabolised by CYP3A. recommended when co-
Diazepam Co-administration with administering darunavir with these
Estazolam darunavir/ritonavir may cause a large sedatives/hypnotics and a lower
Flurazepam increase in the concentration of these dose of the sedatives/hypnotics
Midazolam medicines. should be considered.
(parenteral)
Zolpidem If parenteral midazolam is co- If parenteral midazolam is co-
administered with darunavir co- administered with darunavir with
administered with low dose ritonavir it low dose ritonavir, it should be
may cause a large increase in the done in an intensive care unit (ICU)
concentration of this benzodiazepine. or similar setting, which ensures
Data from concomitant use of close clinical monitoring and
parenteral midazolam with other appropriate medical management in
protease inhibitors suggest a possible case of respiratory depression
3-4 fold increase in midazolam plasma and/or prolonged sedation. Dose
levels. adjustment for midazolam should be
considered, especially if more than
a single dose of midazolam is
administered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tadalafil (HOS-086316) protease (HOS-085623) estazolam (HOS-086165) clorazepate (HOS-086164) diazepam (HOS-085904) zolpidem (HOS-086327) buspirone (HOS-086325) sildenafil (HOS-086162) ritonavir (HOS-084521) flurazepam (HOS-086166) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 4418dc5e5d870dbdffdec96577360a7846fd09dd38b08120ab6e36d180a150e5 · Zeichen 64193–68705 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 63–64
HOS-134634 · Präparat HOS-097580
63
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Recommendations concerning co-
therapeutic areas Geometric mean change (%) administration
For the treatment of Not studied. Concomitant use of A safe and effective dose of sildenafil
pulmonary arterial sildenafil or tadalafil for the for the treatment of pulmonary
hypertension treatment of pulmonary arterial arterial hypertension co-administered
Sildenafil hypertension and boosted darunavir with boosted darunavir has not been
Tadalafil may increase plasma concentrations established. There is an increased
of sildenafil or tadalafil. potential for sildenafil-associated
(CYP3A inhibition) adverse events (including visual
disturbances, hypotension, prolonged
erection and syncope). Therefore, co-
administration of boosted darunavir
and sildenafil when used for the
treatment of pulmonary arterial
hypertension is contraindicated (see
section 4.3).
Co-administration of tadalafil for the
treatment of pulmonary arterial
hypertension with boosted darunavir
is not recommended.
PROTON PUMP INHIBITORS
Omeprazole #
darunavir AUC ↔ Boosted darunavir can be co-
20 mg once daily #
darunavir Cmin ↔ administered with proton pump
#
darunavir Cmax ↔ inhibitors without dose adjustments.
SEDATIVES/HYPNOTICS
Buspirone Not studied. Sedative/hypnotics are Clinical monitoring is recommended
Clorazepate extensively metabolised by when co-administering boosted
Diazepam CYP3A. Co-administration with darunavir with these
Estazolam boosted darunavir may cause a sedatives/hypnotics and a lower dose
Flurazepam large increase in the concentration of the sedatives/hypnotics should be
Midazolam (parenteral) of these medicines. considered.
Zolpidem
If parenteral midazolam is co- If parenteral midazolam is co-
administered with boosted administered with boosted darunavir,
darunavir it may cause a large it should be done in an intensive care
increase in the concentration of this unit (ICU) or similar setting, which
benzodiazepine. Data from ensures close clinical monitoring and
concomitant use of parenteral appropriate medical management in
midazolam with other protease case of respiratory depression and/or
inhibitors suggest a possible 3-4 prolonged sedation. Dose adjustment
fold increase in midazolam plasma for midazolam should be considered,
levels. especially if more than a single dose
of midazolam is administered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tadalafil (HOS-086316) protease (HOS-085623) estazolam (HOS-086165) clorazepate (HOS-086164) diazepam (HOS-085904) zolpidem (HOS-086327) buspirone (HOS-086325) sildenafil (HOS-086162) flurazepam (HOS-086166) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 6377f4fd304b9d7c6481847fbb0c450071fb1a4848818644923dd1099047eab9 · Zeichen 69529–73658 im Abschnitt
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 17–18
HOS-138500 · Präparat HOS-098200
17
PROTON PUMP INHIBITORS
Dexlansoprazole Based on theoretical Symtuza can be co-administered
Esomeprazole considerations, no mechanistic with proton pump inhibitors
Lansoprazole interaction is expected. without dose adjustments.
Omeprazole
Pantoprazole
Rabeprazole
SEDATIVES/HYPNOTICS
Buspirone Based on theoretical considerations Clinical monitoring is
Clorazepate DRV/COBI is expected to increase recommended when
Diazepam these sedative/hypnotic plasma co-administering Symtuza with
Estazolam concentrations. these sedatives/hypnotics and a
Flurazepam (CYP3A inhibition) lower dose of the
Midazolam (parenteral) sedative/hypnotic should be
Zolpidem considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) rabeprazole (HOS-114843) estazolam (HOS-086165) esomeprazole (HOS-087944) pantoprazole (HOS-085167) clorazepate (HOS-086164) diazepam (HOS-085904) zolpidem (HOS-086327) buspirone (HOS-086325) dexlansoprazole (HOS-138501) flurazepam (HOS-086166) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage d66918b1ab817bed50d64727b6ed8e70c3661e6e6c213975acff37740c998350 · Zeichen 42940–44015 im Abschnitt
Wechselwirkungen · Tukysa
TUKYSA 50 mg film-coated tablets TUKYSA 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-145571 · Präparat HOS-099373
CYP3A substrates
Tucatinib is a strong CYP3A inhibitor. A clinical drug interaction study found that co-administration
of tucatinib with midazolam (a sensitive CYP3A substrate) resulted in an increase in midazolam
concentrations (3.0-fold Cmax (90% CI: 2.6, 3.4) and 5.7-fold AUC (90% CI: 5.0, 6.5)).
Co-administration of tucatinib with sensitive CYP3A substrates such as alfentanil, avanafil, buspirone,
darifenacin, darunavir, ebastine, everolimus, ibrutinib, lomitapide, lovastatin, midazolam, naloxegol,
saquinavir, simvastatin, sirolimus, tacrolimus, tipranavir, triazolam, and vardenafil may increase their
systemic exposures which may increase the toxicity associated with a CYP3A substrate. Concomitant
use of tucatinib with CYP3A substrates, when minimal concentration changes may lead to serious or
life-threatening toxicities, should be avoided. If concomitant use is unavoidable, the CYP3A substrate
dosage should be decreased in accordance with the concomitant medicinal product SmPC.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) lovastatin (HOS-086157) lomitapide (HOS-086160) ebastine (HOS-132877) simvastatin (HOS-086158) avanafil (HOS-086161) naloxegol (HOS-109428) lead (HOS-085592) saquinavir (HOS-084522) tacrolimus (HOS-085202) darunavir (HOS-086181) everolimus (HOS-086310) buspirone (HOS-086325) sirolimus (HOS-085172) darifenacin (HOS-113065) triazolam (HOS-086168) tipranavir (HOS-086184) ibrutinib (HOS-086226) midazolam (HOS-086167) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-25T09:31:00Z · SHA-256 adbbdb974aceeb49def28fd6967671862f72abd36a9da5eedfd1b7260c9b3db3 · Passage 4b3fd5f017560760570faed906723a4854964f126b379e0e81d431b1065811bc · Zeichen 1850–2847 im Abschnitt
Wechselwirkungen · Retsevmo
Retsevmo 40 mg hard capsules Retsevmo 80 mg hard capsules · Abschnitt 4.5 · PDF-Seite 10
HOS-146815 · Präparat HOS-099572
Sensitive CYP3A4 substrates
Selpercatinib increased Cmax and AUC of midazolam (a CYP3A4 substrate) by approximately 39%
and 54%, respectively. Therefore, concomitant use with sensitive CYP3A4 substrates, (e.g., alfentanil,
avanafil, buspirone, conivaptan, darifenacin, darunavir, ebastine, lomitapide, lovastatin, midazolam,
naloxegol, nisoldipine, saquinavir, simvastatin, tipranavir, triazolam, vardenafil), should be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) lovastatin (HOS-086157) lomitapide (HOS-086160) ebastine (HOS-132877) simvastatin (HOS-086158) conivaptan (HOS-128737) avanafil (HOS-086161) naloxegol (HOS-109428) saquinavir (HOS-084522) nisoldipine (HOS-114251) darunavir (HOS-086181) buspirone (HOS-086325) darifenacin (HOS-113065) triazolam (HOS-086168) tipranavir (HOS-086184) midazolam (HOS-086167) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-03T11:29:00Z · SHA-256 ea39918a3fb80726ed18974b1aa44d085db9e48e01020d5741da30903ff4eadc · Passage cfdd98013721cec7702691e58a399d79c90849bc3f50350904fe7bfe355bcc04 · Zeichen 2240–2668 im Abschnitt
Wechselwirkungen · Retsevmo
Retsevmo 40 mg film-coated tablets Retsevmo 80 mg film-coated tablets Retsevmo 120 mg film-coated tablets Retsevmo 160 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 43
HOS-146887 · Präparat HOS-099572
Sensitive CYP3A4 substrates
Selpercatinib increased Cmax and AUC of midazolam (a CYP3A4 substrate) by approximately 39%
and 54%, respectively. Therefore, concomitant use with sensitive CYP3A4 substrates, (e.g., alfentanil,
avanafil, buspirone, conivaptan, darifenacin, darunavir, ebastine, lomitapide, lovastatin, midazolam,
naloxegol, nisoldipine, saquinavir, simvastatin, tipranavir, triazolam, vardenafil), should be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) lovastatin (HOS-086157) lomitapide (HOS-086160) ebastine (HOS-132877) simvastatin (HOS-086158) conivaptan (HOS-128737) avanafil (HOS-086161) naloxegol (HOS-109428) saquinavir (HOS-084522) nisoldipine (HOS-114251) darunavir (HOS-086181) buspirone (HOS-086325) darifenacin (HOS-113065) triazolam (HOS-086168) tipranavir (HOS-086184) midazolam (HOS-086167) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-03T11:29:00Z · SHA-256 ea39918a3fb80726ed18974b1aa44d085db9e48e01020d5741da30903ff4eadc · Passage cfdd98013721cec7702691e58a399d79c90849bc3f50350904fe7bfe355bcc04 · Zeichen 2184–2612 im Abschnitt
Wechselwirkungen · Voranigo
Voranigo 10 mg film-coated tablets Voranigo 40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-152401 · Präparat HOS-100749
Co-administration of vorasidenib with sensitive substrates of CYP2B6, CYP2C8, CYP2C9,
CYP2C19, or CYP3A4 without narrow therapeutic index (including, but not limited to, bupropion,
buspirone, celecoxib, darunavir, ibrutinib, midazolam, repaglinide, saquinavir, tipranavir, and
triazolam) may decrease the plasma concentrations of these medicinal products. Consider alternative
therapies that are not sensitive substrates of these enzymes during treatment with vorasidenib.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) celecoxib (HOS-113199) saquinavir (HOS-084522) darunavir (HOS-086181) buspirone (HOS-086325) triazolam (HOS-086168) repaglinide (HOS-086935) tipranavir (HOS-086184) ibrutinib (HOS-086226) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-27T16:33:00Z · SHA-256 2232f34043666605447d216a0f9efae95496605e48741a446bf6879643808d62 · Passage 500297f228cb32f64670ee13d216d70156c600213a7133b97ff760620eb23701 · Zeichen 2277–2749 im Abschnitt
Wechselwirkungen · Etcamah
Etcamah 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-153211 · Präparat HOS-100955
CYP3A4/5 substrates
In a clinical study, concomitant use of camizestrant increased midazolam, a sensitive CYP3A4/5
substrate, geometric mean Cmax by 1.50-fold and AUC by 1.99-fold respectively, therefore,
camizestrant is a weak inhibitor of CYP3A4/5. Camizestrant should be used with caution when co-
administered with sensitive CYP3A4/5 substrates (including but not limited to: budesonide, buspirone,
dronedarone, ivabradine, lurasidone, midazolam, quetiapine, sildenafil and simvastatin). Narrow
therapeutic index CYP3A4/5 substrates (e.g. alfentanil and fentanyl) may require dose adjustment and
should be monitored closely.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) alfentanil (HOS-109375) dronedarone (HOS-086144) simvastatin (HOS-086158) budesonide (HOS-086332) ivabradine (HOS-109426) buspirone (HOS-086325) sildenafil (HOS-086162) fentanyl (HOS-086196) camizestrant (HOS-153187) lurasidone (HOS-086148) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:07:16Z · SHA-256 b50ea6ed7223cee8c2b96a46475d89e0843fb8c57083f80f60c2957e00e303a8 · Passage b48da137da5c7aa2002ae59ccfa3acaa45843737fb49c09a04132b8ab6f6fdd6 · Zeichen 3326–3954 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.